STATUTORY INSTRUMENTS

2018 No. 1356

DANGEROUS DRUGS

The Misuse of Drugs Act 1971 (Amendment) Order 2018

Made---12th December 2018Coming into force-1st April 2019

At the Court at Buckingham Palace, the 12th day of December 2018

Present,

The Queen's Most Excellent Majesty in Council

In accordance with section 2(5) of the Misuse of Drugs Act $1971(\mathbf{a})$ a draft of this Order has been laid before Parliament on the recommendation of the Advisory Council on the Misuse of Drugs and approved by a resolution of each House of Parliament.

Accordingly, Her Majesty, in exercise of the powers conferred upon Her by section 2(2) of that Act, is pleased, by and with the advice of Her Privy Council, to order as follows:

Citation and commencement

1. This Order may be cited as the Misuse of Drugs Act 1971 (Amendment) Order 2018 and comes into force on the 1st April 2019.

Amendments to the Misuse of Drugs Act 1971

2.—(1) The following amendments are made to Schedule 2 to the Misuse of Drugs Act 1971.

(2) In paragraph 1(b) of Part 3 (which specifies the drugs which are subject to control under that Act as Class C drugs)—

(a) after "Furazabol." insert-

"Gabapentin (1-(aminomethyl)cyclohexaneacetic acid).", and

(b) after "Prasterone." insert-

"Pregabalin ((S)-3-(aminomethyl)-5-methylhexanoic acid).".

Richard Tilbrook Clerk of the Privy Council

 ⁽a) 1971 c. 38. Schedule 2 has been amended by section 21 of the Drugs Act 2005 (c. 17) and S.I. 1973/771, 1975/421, 1977/1243, 1979/299, 1983/765, 1984/859, 1985/1995, 1986/2230, 1989/1340, 1990/2589, 1995/1966, 1996/1300, 1998/750, 2001/3932, 2003/1243, 2003/3201, 2005/3178, 2006/3331, 2008/3130, 2009/3209, 2010/1207, 2010/1833, 2011/744, 2012/1390, 2013/239, 2014/1106, 2014/1352, 2014/3271, 2015/215, 2016/1109, 2017/634 and 2017/1114.

EXPLANATORY NOTE

(This note is not part of the Order)

This Order brings certain drugs under the control of the Misuse of Drugs Act 1971. Article 2(2) of this Order brings the compounds known as Pregabalin and Gabapentin under permanent control as Class C drugs under that Act.

A full impact assessment of the effect that this instrument will have on the costs of business, the voluntary sector and the public sector is available at https://legislation.gov.uk.

£4.90

UK201812041024 12/2018 19585



[©] Crown copyright 2018

Printed and published in the UK by The Stationery Office Limited under the authority and superintendence of Jeff James, Controller of Her Majesty's Stationery Office and Queen's Printer of Acts of Parliament.